Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 28.00
+1.65 (6.26%)
Jan 22, 2026, 1:17 PM CST
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.56 billion as of January 21, 2026. Its market cap has increased by 30.45% in one year.
Market Cap
1.56B
Enterprise Value
1.40B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
28.00
Market Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.56B, an increase of 35.03%. That is a compound annual growth rate of 4.29%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 1.56B | -6.06% |
| Dec 31, 2025 | 1.67B | 36.50% |
| Dec 31, 2024 | 1.22B | -9.95% |
| Dec 29, 2023 | 1.36B | -8.36% |
| Dec 30, 2022 | 1.48B | -38.27% |
| Dec 30, 2021 | 2.40B | 63.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 25, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 254.20B |
| PharmaEssentia | 213.40B |
| Lotus Pharmaceutical | 84.02B |
| Heron Neutron Medical | 69.56B |
| Bora Pharmaceuticals Co., LTD. | 65.48B |
| Oneness Biotech | 33.73B |
| Lumosa Therapeutics | 31.25B |
| Center Laboratories | 31.09B |